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ABSTRACT
The initiation and progression of breast cancer have been recognized to be 
secondary to the accumulation of genetic mutations, which eventually lead to 
aberrant cellular function. Both inherited and sporadic genetic mutations might 
result in the activation of oncogenes and inactivation of tumor suppressor genes. 
Recent discovery revealed that reversible alterations in histone proteins and 
deoxyribonucleic acid (DNA) might also lead to tumorigenesis, thus introducing 
a novel term to the field of cancer research: epigenetics.  Epigenetics refers to 
the study of heritable changes in gene regulation that do not involve a change in 
the DNA sequence. The most frequently discussed topic in epigenetics of breast 
cancer is promoter DNA methylation. DNA methylation is one of the hallmarks 
of cancer and plays a crucial role in oncogenesis, i.e. transcription blockade, 
supporting the notion that cellular inhibition might take place. Compared to normal 
tissues, double to triple hypermethylation occurs in cancerous cells. 
Detection of aberrantly-methylated CpG islands in promoter region of several 
genes in DNA sample derived from nipple aspirates, serum, or cancer tissue is 
associated with downregulation of gene expression and loss of function that 
would then lead to early stages of breast cancer with poorer prognosis. DNA 
methylation has been identified as signature for TNBC. Methylation of BRCA1 
gene is frequently demonstrated in young, estrogen receptor-negative breast 
cancer patients. BRCA1 methylation in premenopausal women with sporadic 
breast cancer in West Sumatra region has been higher than in Western women, 
thus signifying the difference of methylation profile across race and socioeconomic 
status.
DNA methylation might be used in enhancement of current breast cancer 
classification. There is such distinction between methylation and gene expression 
profiles of breast cancers; that not all methylation profiles fit within the same 
molecular subtype. Specific gene methylation profiles are identified as basal-
like, luminal A and HER2-overexpressing breast cancers. A number of studies 
have analyzed the methylation status of BRCA1, a key player in TNBC. One 
study demonstrated that BRCA1 promoter was methylated in TNBC, proven 
by the increasing sensitivity of TNBC cell lines to PARP inhibitors. In addition, 
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BRCA1 methylation quantity was higher in patients with complete response to 
neoadjuvant chemotherapy than in non-responders. 
Epigenetics is now the cutting edge of cancer research.  Advances in this field 
would have major implications in diagnosis, prevention, treatment of cancer, and 
formulation of new epigenetically-targeted anticancer drugs. 
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